Colistimethate Sodium Injection IP 3 Million IU - BUCOLIS 3 MIU Injection

BUCOLIS 3 MIU Injection – Critical-Line Defense Against Multi-Drug Resistant Infections

BUCOLIS 3 MIU Injection contains Colistimethate Sodium Injection IP 3 Million IU per vial, a prodrug of colistin (Polymyxin E), a potent cyclic polypeptide antibiotic. It works by disrupting the bacterial cell membrane, causing leakage and cell death. This antibiotic is reserved for the treatment of severe infections caused by multidrug-resistant (MDR) gram-negative bacteria, commonly seen in ICU and hospital-acquired infection cases.

Key Benefits of BUCOLIS 3 MIU Injection  – Colistimethate Sodium 3 Million IU
✅ Last-Resort Antibiotic for MDR Infections: Effective against life-threatening infections caused by resistant gram-negative bacteria.
✅ Flexible Dosing Options: Available in various IU strengths to suit critical care, pediatric, and renal-compromised patients.
✅ Prodrug for Safer Administration: Colistimethate delivers colistin in a form that reduces the risk of kidney and nerve toxicity when monitored properly.

Recommended by Specialists:
👨‍⚕️Infectious Disease Specialists: For managing infections caused by MDR organisms such as Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae.
👨‍⚕️Critical Care Specialists: Used in treating ventilator-associated pneumonia (VAP), sepsis, and nosocomial infections.
👨‍⚕️Pulmonologists: Effective in chronic respiratory infections, including cystic fibrosis and bronchiectasis involving resistant pathogens.

Indications:
✅ Hospital-Acquired Pneumonia
✅ Ventilator-Associated Pneumonia (VAP)
✅ Bloodstream Infections (MDR Gram-Negative Bacteria)
✅ Urinary Tract Infections (Resistant Strains)
✅ Intra-abdominal Infections
✅ Septicemia due to Carbapenem-Resistant Organisms (CRO)